General American Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

General American Investors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.7M	Buy	36,362 +5,000	+16%	+$3.4M	1.34%	25
2026 Q1	$24.2M	Hold	31,362	–	–	1.59%	21
2025 Q4	$24.2M	Hold	31,362	–	–	1.37%	23
2025 Q3	$17.6M	Buy	31,362 +21,486	+218%	+$12.1M	1.02%	32
2025 Q2	$5.18M	Sell	9,876 -5,000	-34%	-$2.79M	0.33%	60
2025 Q1	$9.43M	Hold	14,876	–	–	0.69%	42
2024 Q4	$10.6M	Buy	14,876 +3,000	+25%	+$2.52M	0.74%	43
2024 Q3	$12.5M	Sell	11,876 -2,700	-19%	-$3M	0.86%	41
2024 Q2	$15.3M	Hold	14,576	–	–	1.07%	29
2024 Q1	$14M	Sell	14,576 -2,000	-12%	-$1.9M	1%	29
2023 Q4	$14.6M	Hold	16,576	–	–	1.15%	24
2023 Q3	$13.6M	Hold	16,576	–	–	1.22%	24
2023 Q2	$11.9M	Buy	16,576 +1,500	+10%	+$1.16M	1.04%	33
2023 Q1	$12.4M	Hold	15,076	–	–	1.17%	29
2022 Q4	$10.9M	Sell	15,076 -3,000	-17%	-$2.21M	1.06%	34
2022 Q3	$12.5M	Sell	18,076 -3,000	-14%	-$1.89M	1.3%	30
2022 Q2	$12.5M	Sell	21,076 -2,000	-9%	-$1.3M	1.25%	31
2022 Q1	$16.1M	Sell	23,076 -7,000	-23%	-$4.43M	1.32%	28
2021 Q4	$19M	Buy	30,076 +14,075	+88%	+$8.65M	1.49%	22
2021 Q3	$9.68M	Buy	16,001 +3,000	+23%	+$1.86M	0.82%	43
2021 Q2	$7.26M	Buy	13,001 +1,500	+13%	+$760K	0.61%	49
2021 Q1	$5.44M	Buy	+11,501	New	+$5.6M	0.51%	53

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

General American Investors's REGN Position: Q2 2026 in Review

General American Investors increased its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, buying an estimated $3.4M and bringing the position to 36,362 shares worth $22.7M. The position accounts for 1.34% of the portfolio, ranked #25.

General American Investors first reported a position in REGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $24.2M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

General American Investors held 36,362 shares of Regeneron Pharmaceuticals worth $22.7M as of Q2 2026.
General American Investors bought 5,000 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4M.
Regeneron Pharmaceuticals made up 1.34% of General American Investors's portfolio in Q2 2026, its #25 holding.
General American Investors first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
General American Investors's Regeneron Pharmaceuticals position peaked at $24.2M in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on General American Investors's 13F filing for Q2 2026, filed 31 Jul 2026.